Evaluating Novel Drug Candidates for Fragile X Using the Live Mouse Tracker

September 4, 2025

This grant is funding AI-driven drug discovery, advanced mouse behavior tracking, and gene expression analysis to uncover new treatments for Fragile X syndrome.

Read More »

Versatile Drug Screening Platform for Fragile X Syndrome

November 2, 2022

Combinations of drugs may be needed to treat Fragile X syndrome. How can we find the best combinations in the ideal doses? This project tackles this challenge.

Read More »
Frank Kooy lab

GABA-A Receptor in Fragile X Syndrome

November 24, 2021

Published results from Dr. Frank Kooy reveal how GABAA receptor changes may hold the key to treating Fragile X syndrome.

Read More »

Ganaxolone Fragile X Clinical Trial Showed Disappointing Results

February 7, 2019

Ganaxolone, an experimental drug from Marinus Pharmaceuticals which targets GABA receptors, did not show promise for Fragile X syndrome in a clinical trial.

Read More »
Frank Kooy, PhD, at University of Antwerp

Clinical Trial of Ganaxolone in Patients with Fragile X Syndrome

September 2, 2017

With a $90,000 grant from FRAXA Research Foundation funded during 2014-2015, Dr. Frank Kooy and colleagues at the University of Antwerp are conducting a double blind crossover trial of ganaxolone in patients with Fragile X syndrome. Results of this study were mixed (see Marinus: Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome.)

Read More »
Frank Kooy lab

A Kinase Assay as a Biomarker for Fragile X Syndrome

January 15, 2017

With a $90,000 grant from FRAXA Research Foundation over 2017-2018, Dr. Frank Kooy at the University of Antwerp, Belgium, is investigating whether phosphorylation abnormalities are a suitable biomarker for the Fragile X syndrome.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)